CDC6 as a pan-cancer immunological and prognostic biomarker and its role in suppressing melanoma malignancy

Abstract Background: Cell division cycle 6 (CDC6) is a key licensing factor for DNA replication in the G1 and S phases. Besides initiating replication, CDC6 also helps establish and maintain the S-M checkpoint, ensuring genomic stability. Emerging evidence highlights its dysregulation in various cancers, implicating CDC6 in tumor progression and therapy resistance. However, a comprehensive pan-cancer analysis evaluating its diagnostic, prognostic and immunomodulatory potential remains lacking, underscoring the need for further investigation. Methods: By integrating multi-omics datasets from The Cancer